Modality
Vaccine
MOA
PI3Ki
Target
PARP
Pathway
Sphingolipid
OCDNMOSDCRC
Development Pipeline
Preclinical
~Jul 2011
→ ~Oct 2012
Phase 1
~Jan 2013
→ ~Apr 2014
Phase 2
~Jul 2014
→ ~Oct 2015
Phase 3
~Jan 2016
→ ~Apr 2017
NDA/BLA
~Jul 2017
→ ~Oct 2018
Approved
Jan 2019
→ Dec 2030
ApprovedCurrent
NCT07601826
2,740 pts·NMOSD
2019-01→2025-08·Recruiting
NCT05303356
1,859 pts·OCD
2024-09→2028-06·Not yet recruiting
NCT05313866
1,594 pts·NMOSD
2020-04→2030-12·Terminated
+1 more trial
7,102 total pts3 indications
CompletedCurrentUpcoming
Catalysts (3)
2025-08-068mo agoPh3 Readout· NMOSD
2028-06-052.2y awayPh3 Readout· OCD
2030-12-094.7y awayPh3 Readout· NMOSD
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Recruit…
Approved
Termina…
Approved
Complet…
Approved
Not yet…
Catalysts
Ph3 Readout
2025-08-06 · 8mo ago
NMOSD
Ph3 Readout
2028-06-05 · 2.2y away
OCD
Ph3 Readout
2030-12-09 · 4.7y away
NMOSD
RecruitingCompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07601826 | Approved | NMOSD | Recruiting | 2740 | Biomarker |
| NCT05303356 | Approved | OCD | Not yet recr... | 1859 | SRI-4 |
| NCT05313866 | Approved | NMOSD | Terminated | 1594 | SeizFreq |
| NCT03781788 | Approved | CRC | Completed | 909 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| REG-861 | Regeneron | Phase 2 | PARP |